Product Images Lamivudine
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 3 images provide visual information about the product associated with Lamivudine NDC 57237-274 by Rising Pharma Holdings, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1. Virologic Response through Week 48, EPV20001a,b (Intent-to-Treat) - lamivudine figure1
The image shows a graph titled "Figure 1. Virologic Response through Week 48, EPV200012.(Intent-to-Treat)" with two lines labeled "Lamivudine 150 mg twice daily" and "Lamivudine 300 mg once daily". The x-axis shows the treatment time in weeks ranging from 0 to 48, while the y-axis shows the proportion of subjects with HIV-1 RNA <400 copies/mL. The graph indicates that the group given Lamivudine 150 mg twice daily had a higher proportion of subjects with HIV-1 RNA <400 copies/mL over the 48 weeks.*
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL -10 mg/mL (240 mL Bottle Label) - lamivudine figure2
This is an oral solution of Lamivudine, with each mL containing 10mg of the same. The usual dosage can be referred to by checking the package insert. It is advised to store the solution between temperatures 20°C to 25°C. The solution is distributed by Rising Health, LLC and was made in India. The packaging comes with a warning to keep the solution out of reach of children. The code printed on the packaging is TS/DRUGS/19/1993 while printing dotted lines are not to be printed.*
Chemical Structure - lamivudine structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
